Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
RANDOX LABORATORIES
Bio-Rad Diabetes Division

Spinal Fluid Biomarkers Predict Cognitive Decline in Individuals with Familial Risk of Alzheimer's Disease

By Labmedica International staff writers
Posted on 31 Oct 2013
Determination of two biomarkers in cerebrospinal fluid (CSF) allows prediction of development of cognitive impairment up to five years before appearance of symptoms in normal patients with familial risk of Alzheimer's disease.

Investigators at Johns Hopkins University (Baltimore, MD, USA) measured beta-amyloid 1–42 (Abeta1–42), total tau (t-tau), and phosphorylated tau (p-tau) proteins in CSF collected for the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) project between 1995 and 2005, from 265 middle-aged healthy volunteers. Approximately three-quarters of this group had a close family member with Alzheimer’s disease, an indication of higher than normal risk of developing the disorder. Biochemical measurements and assessment of cognitive ability were repeated at yearly intervals.

Results revealed that the mean time from baseline to onset of mild cognitive symptoms was 5.41 years. This decline in cognitive ability was paralleled by increase in the levels of phosphorylated tau and beta amyloid found in CSF. The rate of change over time in the ratio of phosphorylated tau protein to beta amyloid was also predictive, with elevated p-tau indicating increased likelihood of development of cognitive symptoms.

“We wondered if we could measure something in the cerebral spinal fluid when people are cognitively normal to give us some idea of when they will develop difficulty,” said contributing author Dr. Marilyn Albert, professor of neurology at Johns Hopkins University. “The answer is yes.”

“When we see patients with high blood pressure and high cholesterol, we do not say we will wait to treat you until you get congestive heart failure. Early treatments keep heart disease patients from getting worse, and it is possible the same may be true for those with presymptomatic Alzheimer’s. But it has been hard to see Alzheimer’s disease coming, even though we believe it begins developing in the brain a decade or more before the onset of symptoms.”

The investigators pointed out that the biomarker ratio at this point was not accurate enough to predict precisely whether a particular individual is progressing to dementia, and further analysis of information about the group over time is needed.

The study was published in the October 16, 2013, online edition of the journal Neurology.

Related Links:
Johns Hopkins University


DIASYS DIAGNOSTIC SYSTEMS
KARL HECHT GMBH & CO KG
77 ELEKTRONIKA

Channels

Hematology

view channel

Magnetic Resonance Improves Approach to Measuring Hemostasis Parameters

Two studies evaluating a magnetic resonance based detector for hemostasis measurements found its multiplex results to be rapid and accurate using lower blood volumes. At the International Society on Thrombosis and Hemostasis (ISTH) 2015 Congress (Toronto, Canada), T2 Biosystems, Inc. (Lexington, MA, USA) presented results... Read more

Lab Tech.

view channel
Image: Verigene System instrumentation consists of a Verigene Reader and one or multiple Verigene Processor SPs (Photo courtesy of Nanosphere).

Directed Molecular Diagnostic Tests Highlight Recent Microbiology Conference

The performance of a series of directed molecular diagnostic tests was confirmed by several studies presented at a recent microbiology conference. Nanosphere (Northbrook, IL, USA) manufactures tests... Read more

Industry News

view channel

QIAGEN Expands Diagnostics Menu in Partnership with Seegene

In a new collaboration, Seegene Inc. (Soul, Republic of Korea) will use its proprietary next-generation qPCR technology in developing new multiplex assays for the flagship platform of Qiagen NV (Venlo, Netherlands and Hilden, Germany). Seegene will develop a menu of multiplex assay panels for the modular QIAsymphony... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.